Patent Ductus Arteriosus (PDA) Device Closure in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS — HEMODYNAMIC CRITERIA:

• Symptomatic PDA of any age with pulmonary-to-systemic flow ratio (Qp:Qs) ≥ 1.5:1 confirmed on cardiac catheterization or Doppler echocardiography

• Asymptomatic moderate-to-large PDA with evidence of left ventricular volume overload (left atrial enlargement, LV end-diastolic dimension z-score > +2 on echo)

• Small 'silent' PDA in adults with a history of infective endocarditis or at high endocarditis risk (professional guidelines vary; most centers close these)

• Body weight ≥ 6 kg for standard Amplatzer Duct Occluder (ADO-I) deployment; newer ADO-II and Occlutech Duct Occluder devices extend candidacy to infants 3–5 kg

• Pulmonary vascular resistance index (PVRI) < 4–6 Wood units·m² with a net left-to-right shunt (reversibility testing with 100% O₂ or inhaled NO if borderline)

• REQUIRED PRE-PROCEDURE DIAGNOSTICS:

• Transthoracic Echocardiography (TTE) with color Doppler: PDA diameter at pulmonary end, ampulla dimensions, Krichenko morphological type, Qp:Qs estimation, LV/LA dimensions, estimated RVSP/PAP

• Transesophageal Echocardiography (TEE) or 3D Echo: in older children and adults for precise ampulla measurement and device sizing

• Cardiac Catheterization with oximetry run: mandatory when PAH is suspected (PVRI measurement, vasoreactivity testing with inhaled nitric oxide 20–40 ppm)

• Chest X-ray: cardiomegaly index, pulmonary plethora, lung field assessment

• 12-lead ECG: biventricular hypertrophy patterns, arrhythmia screening

• Complete Blood Count (CBC), coagulation profile (PT/INR, aPTT), renal function panel (creatinine, eGFR), blood grouping and cross-matching

• CT Pulmonary Angiography or MRI: occasionally required for complex anatomy, anomalous pulmonary venous drainage co-assessment, or pre-surgical planning

• Nasopharyngeal culture / dental clearance: to exclude active infection prior to device implantation

• CONTRAINDICATIONS (ABSOLUTE):

• Eisenmenger syndrome: PVRI ≥ 8 Wood units·m² with net right-to-left shunting (closure would precipitate acute right heart failure)

• Active infective endocarditis or bacteremia at time of procedure

• PDA anatomy incompatible with any available device (e.g., true window-type PDA < 2 mm length — surgical ligation preferred)

• Severe contrast allergy without available pre-medication protocol (relative; managed with steroid/antihistamine prophylaxis)

• Intracardiac thrombus at catheter access sites

• RELATIVE CONTRAINDICATIONS / SPECIAL CONSIDERATIONS:

• Premature neonates < 1 kg: transcatheter approach technically feasible in experienced centers using Piccolo Occluder (FDA-approved down to 700 g), but surgical ligation or pharmacological closure with indomethacin/ibuprofen/acetaminophen remains first-line at most institutions

• Concurrent congenital heart defects requiring surgical correction: combined or staged approaches individualized by multidisciplinary team

PHARMACOLOGICAL CLOSURE (Neonates and Premature Infants Only):

Indomethacin (COX non-selective inhibitor, 0.1–0.25 mg/kg IV every 12–24 hours × 3 doses) or ibuprofen lysine (10 mg/kg then 5 mg/kg × 2 doses) reduce prostaglandin E2-mediated ductal patency, achieving closure in 70–80% of preterm infants when administered within the first 1–2 weeks of life. Oral/IV acetaminophen (paracetamol) is an emerging, better-tolerated alternative with comparable efficacy data in recent randomized trials. Pharmacological therapy is not effective in term neonates or older patients due to mature ductal histology (fibromuscular transformation). Failure or contraindication to pharmacological closure (renal impairment, thrombocytopenia, active necrotizing enterocolitis, intracranial hemorrhage) mandates transcatheter or surgical intervention.

TRANSCATHETER DEVICE CLOSURE (Preferred Standard of Care — All Age Groups ≥ 3 kg in Suitable Anatomy):

Performed in a cardiac catheterization laboratory under general anesthesia (infants/children) or conscious sedation (adolescents/adults), with continuous fluoroscopic guidance and real-time intracardiac or transesophageal echocardiographic monitoring.

1. Amplatzer Duct Occluder I (ADO-I, Abbott/St. Jude Medical): The most globally validated device. A conical nitinol mesh plug with a retention disc on the aortic end, available in diameters 4–16 mm. Delivered via femoral venous access (antegrade approach) or femoral arterial access (retrograde). Gold standard for Krichenko Type A (conical) and Type E (elongated tubular) morphologies.

2. Amplatzer Duct Occluder II (ADO-II): Symmetrical, low-profile nitinol device suitable for small ducts (1.5–5.5 mm) and tubular/tortuous anatomies. Can be deployed from venous or arterial side, making it versatile for Type B, C, and D ducts. Preferred in small infants (3–6 kg) due to its smaller sheath profile (4–5 Fr).

3. Occlutech Duct Occluder (ODO): European-designed double-disc device with a waist, offering enhanced stability in short or window-type ducts; 3D-printed patient-specific sizing templates increasingly used in complex cases.

4. Piccolo Occluder (Abbott): The only FDA-approved device specifically for transcatheter PDA closure in premature infants (700 g – 2 kg, gestational age ≥ 28 weeks). Delivered via 4 Fr sheath through femoral vein. Real-time TEE guidance essential. Centers in India and the UAE with dedicated neonatal catheterization suites now routinely offer this approach, avoiding thoracotomy in the most vulnerable patients.

5. MSDOS (Micro-spiral Coil Closure): Gianturco or Flipper coils for very small (< 2.5 mm) restrictive PDAs; largely superseded by ADO-II but still used in select cases.

INTRACARDIAC ECHOCARDIOGRAPHY (ICE)-GUIDED CLOSURE: An advanced technique eliminating the need for general anesthesia in cooperative adolescents and adults. An ICE catheter (AcuNav, 8–10 Fr) is introduced via femoral vein, providing real-time cardiac imaging without esophageal intubation, reducing anesthesia risk and accelerating recovery.

SURGICAL PDA LIGATION:

Reserved for: (1) premature neonates < 700 g or with vascular access precluding catheterization; (2) window-type PDAs with insufficient length for device landing zone; (3) failure or device embolization after transcatheter attempt.

Approaches include:

• Video-Assisted Thoracoscopic Surgery (VATS) Ligation: Three-port left thoracoscopic approach; 5 mm ports; titanium clip application under direct visualization. Minimally invasive, no rib spreading, excellent cosmesis. Standard of care for surgical ligation in centers with pediatric VATS expertise.

• Open Left Posterolateral Thoracotomy (Mini-thoracotomy, 3–4 cm): Traditional approach; 100% closure rate; used in neonates and complex anatomy where VATS access is limited.

• Robot-Assisted Ligation: Available at select tertiary centers; benefits marginal over VATS for this indication; reserved for adult or adolescent patients with concurrent intracardiac pathology requiring robotic-assisted surgery.

HYBRID APPROACH (Perventricular Device Closure):

In low-weight infants where femoral vessel caliber is insufficient for standard sheath passage, a surgical mini-sternotomy or left mini-thoracotomy exposes the right ventricle, allowing needle puncture and direct device delivery into the pulmonary artery without cardiopulmonary bypass. This hybrid strategy combines the benefits of transcatheter device stability with direct surgical access, and is offered at select high-volume congenital heart centers in India (AIIMS Delhi, Amrita Institute, Narayana Health) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital).

PHASE 1 — PRE-ARRIVAL CONSULTATION (2–4 weeks before travel):

• Patient family submits echocardiography reports, catheterization data (if prior), growth charts, and medical records to GAF Healthcare's medical coordination team

• Remote case review by the destination center's pediatric cardiologist and interventional cardiologist; written opinion issued within 48–72 hours

• GAF Healthcare coordinates e-Medical Visa application (India) or entry visa facilitation (UAE) in parallel

• Pre-procedure blood tests, CBC, coagulation, renal panel, blood group arranged at local facility using a standardized requisition form issued by the destination center

• Dental clearance and ENT review for active infection recommended 2 weeks prior

• Anesthesia pre-assessment questionnaire completed remotely for infants under general anesthesia

PHASE 2 — ARRIVAL AND PRE-PROCEDURE WORKUP (Days 1–2 in destination):

• Airport pickup by GAF Healthcare's dedicated medical escort team; patient and family transferred to pre-arranged hospital-adjacent accommodation

• Day 1: Admission to pediatric cardiology unit; baseline clinical assessment by consultant pediatric cardiologist; repeat TTE/TEE performed with 3D echo dataset acquisition for final device sizing

• Cardiac catheterization laboratory team (interventional cardiologist, cardiac anesthesiologist, perfusionist, echo technician) reviews imaging; device inventory confirmed (ADO-I, ADO-II, Occlutech ODO available)

• Nil by mouth (NPO) from midnight before procedure; IV access established; aspirin 3–5 mg/kg/day started 24 hours pre-procedure (in children > 6 months) for post-device anti-platelet prophylaxis loading

• Family counseling session by GAF Healthcare's patient liaison, explaining procedure timeline, consent documentation, and what to expect

PHASE 3 — THE PROCEDURE (Day 2 or Day 3):

• Duration: 45–90 minutes (transcatheter); 60–120 minutes (VATS surgical ligation)

• Patient transferred to cath lab; general anesthesia induced (infants/children) or conscious sedation administered (adults)

• Femoral venous (and/or arterial) access established under ultrasound guidance; 4–7 Fr sheaths placed

• Diagnostic catheterization: right heart pressures measured; pulmonary vascular resistance calculated; oximetry run performed to confirm Qp:Qs

• PDA crossed via pulmonary artery; angiogram performed in 90° lateral projection to delineate PDA morphology, narrowest diameter, and ampulla dimensions

• Device selected (typically 2–4 mm larger than minimum PDA diameter for ADO-I; matched to narrowest diameter for ADO-II); loaded into delivery catheter; positioned under combined fluoroscopic and TEE/ICE guidance

• Device released; repeat angiogram and echo at 10 minutes to confirm position, absence of aortic/pulmonary obstruction, and residual shunt assessment

• If satisfactory: sheaths removed; hemostasis achieved; patient transferred to pediatric ICU/cardiac step-down unit

PHASE 4 — IMMEDIATE POST-PROCEDURE (Hours 0–24):

• Continuous cardiac monitoring; oxygen saturation, heart rate, blood pressure, pedal pulse checks hourly for 6 hours

• Repeat TTE at 4–6 hours post-procedure: device position confirmed, residual shunt (trivial trace shunts common in first 24 hours — expected; complete sealing by endothelialization in 4–6 weeks)

• Antiplatelet therapy: aspirin 3–5 mg/kg/day continued for 6 months (pediatric dosing); antibiotic prophylaxis per institutional protocol (typically single pre-procedure dose of cefazolin)

• Ambulation permitted 6–8 hours post-procedure once femoral access sites stable

• Oral feeds resumed 4–6 hours post-procedure when fully awake

PHASE 5 — HOSPITAL DISCHARGE (Day 2–3):

• Discharge criteria: stable vital signs, no residual hemodynamically significant shunt on discharge echo, intact bilateral femoral pulses, no groin hematoma, afebrile

• Discharge medications: aspirin (6 months), endocarditis prophylaxis instructions (dental procedures for 6 months post-device implant, per AHA 2021 guidelines)

• Written discharge summary, echo report, fluoroscopy images, and device implant card provided (patient keeps device card for life — important for MRI screening; most modern nitinol devices are MRI-conditional at 1.5T and 3T after 6 weeks)

PHASE 6 — POST-DISCHARGE RECOVERY IN DESTINATION COUNTRY (Days 3–14):

• Outpatient review at Day 3–5: wound check, repeat TTE, 12-lead ECG

• No strenuous physical activity; no swimming or bathing in communal water for 2 weeks

• Groin puncture site care: dry dressing, no heavy lifting

• GAF Healthcare accommodation team arranges serviced apartment for family; local SIM card, translation app access, and 24/7 WhatsApp helpline provided

PHASE 7 — FIT-TO-FLY ASSESSMENT AND DEPARTURE:

• Short-haul flights (< 3 hours): cleared at Day 7–10 if echo stable and no complications

• Long-haul intercontinental flights (> 5 hours): cleared at Day 14–21 pending repeat TTE confirming device stability, complete (or near-complete) shunt occlusion, and no pulmonary hypertensive response

• Aviation medical clearance letter issued by treating cardiologist; GAF Healthcare provides travel assistance letter for airline and customs (device implant documentation)

• Follow-up TTE arranged with patient's home cardiologist at 1 month, 3 months, 6 months, and 12 months